小胶质细胞在慢性创伤性脑病病因与演变中的作用
本文为综述,总结慢性创伤性脑病(CTE)与脑内固有免疫系统小胶质细胞之间联系的当前认识。文章讨论CTE的神经病理基础,包括磷酸化tau蛋白形成神经原纤维缠结并聚集以及β淀粉样蛋白沉积的形成。文章提出小胶质细胞驱动与CTE隐匿起病相关的持续低水平炎症。作者结论认为,首次脑损伤与CTE长期发展之间的潜伏期为治疗干预提供了机会;微管稳定剂、顺式p-tau抗体以及治疗性改变小胶质细胞炎症状态的能力在动物和人体试验中均显示积极结果。
要点
- CTE是创伤性脑损伤后的迟发性进行性神经退行性疾病,脑外伤是日益增长且未被充分认识的公共卫生问题,致残率高且全球相关花费大。
- CTE的神经病理包括磷酸化tau蛋白形成神经原纤维缠结并聚集,以及β淀粉样蛋白沉积的形成。
- 小胶质细胞作为脑内固有免疫细胞,驱动与CTE隐匿起病相关的持续低水平炎症。
- 作者结论认为,首次脑损伤与CTE长期发展之间的潜伏期为治疗干预提供了机会。
- 微管稳定剂、顺式p-tau抗体及治疗性改变小胶质细胞炎症状态在动物和人体试验中均显示积极结果。
研究设计与关键结果
- 综述总结当前对CTE与脑内固有免疫系统小胶质细胞之间联系的认识。
- CTE的神经病理包括磷酸化tau蛋白形成神经原纤维缠结并聚集以及β淀粉样蛋白沉积的形成。
- 小胶质细胞驱动与CTE隐匿起病相关的持续低水平炎症。
- 作者结论认为,首次脑损伤与CTE长期发展之间的潜伏期为治疗干预提供了机会。
- 微管稳定剂、顺式p-tau抗体以及治疗性改变小胶质细胞炎症状态的能力在动物和人体试验中均显示积极结果。
- 下一代测序技术用于研究基因组、转录组和表观遗传信息,将为理解促修复与促损伤基因特征提供机会,从而实现对该高致残性损伤过程的靶向干预。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,首次脑损伤与CTE长期发展之间的潜伏期为治疗干预提供了机会。
- 作者指出,微管稳定剂、顺式p-tau抗体以及治疗性改变小胶质细胞炎症状态的能力在动物和人体试验中均显示积极结果。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Chronic traumatic encephalopathy (CTE) is a progressive neurodegenerative disease that presents as a late sequela from traumatic brain injury (TBI). TBI is a growing and under-recognized public health concern with a high degree of morbidity and large associated global costs. While the immune response to TBI is complex, its contribution to the development of CTE remains largely unknown. In this review, we summarize the current understanding of the link between CTE and the resident innate immune system of the brain-microglia. We discuss the neuropathology underlying CTE including the creation and aggregation of phosphorylated tau protein into neurofibrillary tangles and the formation of amyloid beta deposits. We also present how microglia, the resident innate immune cells of the brain, drive the continuous low-level inflammation associated with the insidious onset of CTE. In this review, we conclude that the latency period between the index brain injury and the long-term development of CTE presents an opportunity for therapeutic intervention. Encouraging advances with microtubule stabilizers, cis p-tau antibodies, and the ability to therapeutically alter the inflammatory state of microglia have shown positive results in both animal and human trials. Looking forward, recent advancements in next-generation sequencing technology for the study of genomic, transcriptomic, and epigenetic information will provide an opportunity for significant advancement in our understanding of prorepair and pro-injury gene signatures allowing for targeted intervention in this highly morbid injury process.
参考来源
- Makinde HM, Just TB, Cuda CM, et al. The Role of Microglia in the Etiology and Evolution of Chronic Traumatic Encephalopathy. Shock. 2017. PMID: 28234788. doi:10.1097/SHK.0000000000000859
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。